Lidocaine Hydrochloride shortage — US supply status & alternatives

Lidocaine Hydrochloride

—

🇦🇺 AUST R 309522 · Accord Healthcare Pty Ltd

In supply · Australia

Xylocaine Mpf

In supply · 🇦🇺 Australia · short in🇺🇸 US🇨🇦 CA

In supply in Australia

Reading today’s signals…

✓ Can I substitute?

Per normal rules

Confirm with prescriber

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Brand names
Active ingredient (INN)	Lidocaine Hydrochloride

Therapeutic category	Auto-created by U.S. Food and Drug Administration — Drug Shortages scraper

Controlled substance	No

Marketing-authorisation holders	Accord Healthcare Pty Ltd, HAMELN PHARMA LTD, FRESENIUS KABI LIMITED, MERCURY PHARMACEUTICALS LIMITED +4 more

Registrations on file	17

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Global API supply base 🇺🇸 FDA Drug Master Files · active Type II

7 API manufacturers

Manufacturers with an active Type II Drug Master File — i.e. cleared to supply this active ingredient into the US market. A proxy for how concentrated the global manufacturing base is.

Low concentration risk

Cambrex Karlskoga ABMoehs Iberica SlDelta Synthetic CO LTDMahendra ChemicalsSwati Spentose Private LTDApex Healthcare LTD+1 more

Manufacturing countries: Sweden, Spain, Taiwan, India · Source: FDA List of Drug Master Files

Recalls official enforcement reports

🇺🇸

LIDOCAINE HYDROCHLORIDE

Huons Co., Ltd. · Apr 2026

Class IIdetails ↗

🇺🇸

LIDOCAINE HYDROCHLORIDE

Huons Co., Ltd. · Apr 2026

Class IIdetails ↗

🇺🇸

LIDOCAINE HYDROCHLORIDE

Pfizer Inc. · Oct 2023

Class Idetails ↗

🇺🇸

LIDOCAINE HYDROCHLORIDE

Pfizer Inc. · Oct 2023

Class Idetails ↗

🇺🇸

LIDOCAINE HYDROCHLORIDE

Teligent Pharma, Inc. · Nov 2021

Class Idetails ↗

🇺🇸

LIDOCAINE HYDROCHLORIDE

Teligent Pharma, Inc. · Nov 2021

Class IIdetails ↗

Registration recordmarketing-authorisation holders

Registrations & marketing-authorisation holders17 registrations · 8 MA holders

Product	Strength	Form	Market	MA holder	Status
LIDOCAINE INTAS 1% lidocaine hydrochloride	1%	—	🇦🇺 AU	Accord Healthcare Pty Ltd	Active
LIDOCAINE ACCORD 1% lidocaine hydrochloride	1%	—	🇦🇺 AU	Accord Healthcare Pty Ltd	Active
LIDOCAINE ACCORD 2% lidocaine hydrochloride	2%	—	🇦🇺 AU	Accord Healthcare Pty Ltd	Active
LIDOCAINE INTAS 2% lidocaine hydrochloride	2%	—	🇦🇺 AU	Accord Healthcare Pty Ltd	Active
Lidocaine Hydrochloride Injection Bp 1% W/V	1%	injection	🇬🇧 GB	HAMELN PHARMA LTD	Active
Lidocaine Hydrochloride Injection Bp 2% W/V	2%	injection	🇬🇧 GB	HAMELN PHARMA LTD	Active
Lidocaine Hydrochloride 0.2% And Glucose 5% Solution For Infusion	0.2%	solution	🇬🇧 GB	FRESENIUS KABI LIMITED	Active
Lidocaine Hydrochloride 0.4% And Glucose 5% Solution For Infusion	0.4%	solution	🇬🇧 GB	FRESENIUS KABI LIMITED	Active
Lidocaine Hydrochloride 1% W/V Solution For	1%	injection	🇬🇧 GB	FRESENIUS KABI LIMITED	Active
Lidocaine Hydrochloride 2% W/V Solution For	2%	injection	🇬🇧 GB	FRESENIUS KABI LIMITED	Active
Lidocaine Hydrochloride 0.5% W/V Solution For	0.5%	injection	🇬🇧 GB	MERCURY PHARMACEUTICALS LIMITED	Active
Lidocaine Hydrochloride 2% W/V Solution For	2%	injection	🇬🇧 GB	MERCURY PHARMACEUTICALS LIMITED	Active
Lidocaine Hydrochloride Noridem	10 MG	injection	🇬🇧 GB	NORIDEM ENTERPRISES LIMITED	Active
Lidocaine Hydrochloride Noridem	20 MG	injection	🇬🇧 GB	NORIDEM ENTERPRISES LIMITED	Active
Lidocaine Hydrochloride/Phenylephrine Hydrochloride	6.5 MG	lidocaine	🇬🇧 GB	PEMBERTON LABORATORIES (UK) LIMITED	Active

+2 more registrations on file

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.